Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 20/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 19/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 18/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 15/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3710765 | 0.81 | CYP3A4 (0.51) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL189904 | 0.75 | NOTUM (0.66) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL3989641 | 0.73 | CYP3A4 (0.53) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL3989642 | 0.73 | NOTUM (0.66) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL564987 | 0.71 | HTT (0.64) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL189618 | 0.68 | ROCK2 (0.48) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL11936095 | 0.68 | FFAR1 (0.63) | CYP3A4CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL31396238 | 0.65 | HTT (0.56) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL333550 | 0.65 | CYP1A2 (0.58) | CYP3A4CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL14071631 | 0.65 | FFAR1 (0.51) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401263-B1 | SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME | SK BIOPHARMACEUTICALS CO LTD (KR) | 2016-02-17 | — | — | EP | disclosed |
| US-8828992-B2 | Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating Parkinson's disease using the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-09-09 | — | — | US | disclosed |
| US-20110301150-A1 | SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. | 2011-12-08 | — | — | US | disclosed |
| WO-2010098600-A2 | SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME | SK HOLDINGS CO., LTD. (KR) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301150-A1 | SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME | MAOB, MAOA, PARK7 | CYP3A4 32/4885CYP2C19 4/4885CYP2C9 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.